Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares gapped down prior to trading on Wednesday . The stock had previously closed at $84.57, but opened at $72.90. Dianthus Therapeutics shares last traded at $72.07, with a volume of 790,177 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Truist Financial boosted their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Price Performance

The stock has a market capitalization of $3.84 billion, a P/E ratio of -17.00 and a beta of 1.18. The company’s 50 day simple moving average is $87.36 and its two-hundred day simple moving average is $64.45.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Ryan Savitz sold 8,224 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president owned 8,224 shares in the company, valued at $738,844.16. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marino Garcia sold 122,918 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 349,551 shares of company stock worth $28,968,156 in the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp grew its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Braidwell LP acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $32,859,000. Finally, Polar Capital Holdings Plc acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $29,434,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.